文献速递肿瘤 PET/CT

18F-FDG PET/MRI对初诊乳腺癌女性治疗管理的影响:一项前瞻性双中心试验结果

Impact of 18F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial.
PubMed 文献 · J Nucl Med · 2024-12-03

这项前瞻性双中心研究纳入208例初诊未治的浸润性乳腺癌女性,比较指南推荐的常规分期与全身18F-FDG PET/MRI(含乳腺专用检查)对UICC分期及治疗决策的影响。联合评估使5/208例(2.4%,95%CI 0.78%-5.2%)发生治疗管理重大改变;PET/MRI正确分期170/208例(81.9%),常规分期正确130/208例(62.5%)。作者结论认为尽管PET/MRI分期诊断更优,常规分期已足以指导治疗管理,PET/MRI对患者管理无影响。

要点

  • 联合18F-FDG PET/MRI使5/208例(2.4%)初诊乳腺癌患者发生治疗管理重大改变。
  • PET/MRI正确判定UICC分期170/208例(81.9%),常规分期正确130/208例(62.5%)。
  • 作者结论:常规分期已足以指导治疗管理,PET/MRI对患者管理无影响。

核心结论

  • 尽管18F-FDG PET/MRI在确定正确UICC分期上优于常规分期,当前指南推荐的常规分期算法已足以对初诊乳腺癌患者进行适当的治疗管理,且18F-FDG PET/MRI对患者管理没有影响。

研究设计与样本

  • 前瞻性双中心研究,纳入208例初诊、未接受过治疗的浸润性乳腺癌女性,所有患者接受指南推荐的常规分期和全身18F-FDG PET/MRI(含乳腺专用检查)。
  • 由多学科肿瘤委员会为每例患者制定两种治疗推荐:一种仅基于常规分期,另一种基于常规分期联合18F-FDG PET/MRI评估。

主要发现

  • 基于常规分期联合18F-FDG PET/MRI评估,208例中5例发生治疗管理重大改变,占研究人群的2.4%(95%CI 0.78%-5.2%)。
  • 在确定UICC分期上,指南分期算法与18F-FDG PET/MRI一致135/208例(64.9%;95%CI 58%-71.4%)。
  • 常规指南算法正确确定UICC分期130/208例(62.5%;95%CI 55.5%-69.1%),18F-FDG PET/MRI正确确定UICC分期170/208例(81.9%;95%CI 75.8%-86.7%)。

关键数值与推荐

  • 治疗管理重大改变:5/208例,2.4%(95%CI 0.78%-5.2%)。
  • UICC分期一致:135/208例,64.9%(95%CI 58%-71.4%)。
  • 常规分期正确UICC分期:130/208例,62.5%(95%CI 55.5%-69.1%)。
  • 18F-FDG PET/MRI正确UICC分期:170/208例,81.9%(95%CI 75.8%-86.7%)。

临床怎么用

  • 原文结论认为当前指南推荐的常规分期算法已足以对初诊乳腺癌患者进行适当的治疗管理,18F-FDG PET/MRI对患者管理没有影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our rationale was to investigate whether 18F-FDG PET/MRI in addition to (guideline-recommended) conventional staging leads to changes in therapeutic management in patients with newly diagnosed breast cancer and compare the diagnostic accuracy of 18F-FDG PET/MRI with that of conventional staging for determining the Union for International Cancer Control (UICC) stage. Methods: In this prospective, double-center study, 208 women with newly diagnosed, therapy-naïve invasive breast cancer were enrolled in accordance with the inclusion criteria. All patients underwent guideline-recommended conventional staging and whole-body 18F-FDG PET/MRI with a dedicated breast examination. A multidisciplinary tumor board served to determine 2 different therapy recommendations for each patient, one based on conventional staging alone and another based on combined assessment of conventional staging and 18F-FDG PET/MRI examinations. Major changes in therapy recommendations and differences between the conventional staging algorithm and 18F-FDG PET/MRI for determining the correct UICC stage were reported and evaluated. Results: Major changes in therapeutic management based on combined assessment of conventional staging and 18F-FDG PET/MRI were detected in 5 of 208 patients, amounting to changes in therapeutic management in 2.4% (95% CI, 0.78%-5.2%) of the study population. In determining the UICC stage, the guideline-based staging algorithm and 18F-FDG PET/MRI were concordant in 135 of 208 (64.9%; 95% CI, 58%-71.4%) patients. The conventional guideline algorithm correctly determined the UICC stage in 130 of 208 (62.5%; 95% CI, 55.5%-69.1%) patients, and 18F-FDG PET/MRI correctly determined the UICC stage in 170 of 208 (81.9%; 95% CI, 75.8%-86.7%) patients. Conclusion: Despite the diagnostic superiority of 18F-FDG PET/MRI over conventional staging in determining the correct UICC stage, the current (guideline-recommended) conventional staging algorithm is sufficient for adequate therapeutic management of patients with newly diagnosed breast cancer, and 18F-FDG PET/MRI does not have an impact on patient management.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jannusch K, Umutlu L, Kirchner J, et al. Impact of 18F-FDG PET/MRI on Therapeutic Management of Women with Newly Diagnosed Breast Cancer: Results from a Prospective Double-Center Trial. J Nucl Med. 2024. PMID: 39389629. doi:10.2967/jnumed.124.268065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。